Exagen's Exciting Participation at ACR 2025
Exagen Inc. (Nasdaq: XGN), a prominent player in autoimmune diagnostics, has made a significant announcement regarding its upcoming participation at the prestigious ACR 2025. The company proudly revealed the acceptance of six abstracts for presentation at the American College of Rheumatology’s Convergence event, which aims to foster advancements in the management and understanding of various autoimmune conditions.
A Focus on Precision Medicine
Among the highlights of Exagen's presence is a special plenary presentation developed in collaboration with Johns Hopkins University. This talk aims to present a novel urinary biomarker panel designed to guide healthcare professionals in the precision management of Lupus Nephritis. This initiative represents an essential stride towards meeting the specific needs of rheumatologists and their patients.
Enhancing Diagnostic Accuracy through Innovation
In addition to the keynote presentation, Exagen will share insightful research findings focused on improving diagnostic accuracy for rheumatoid arthritis (RA). Through investigations into anti-RA33 and anti-PAD4 biomarkers, alongside traditional diagnostic measures, Exagen strives to enhance certainty and early diagnosis for RA patients. These efforts are augmented by advancements in T Cell biomarkers that serve as critical differentiators between systemic lupus erythematosus (SLE) and other similar conditions, thus improving the overall diagnostic precision offered by AVISE® CTD.
Exciting Presentations Scheduled
The event timeline includes a notable Innovation Theater on October 27, where Exagen will bring together respected experts Dr. Alvin Wells and Dr. Vasileios Kyttaris to delve into the decade of validation behind AVISE CTD. Their discussion will illuminate how this platform has influenced lupus diagnostic accuracy and opened pathways for innovative biomarkers in seronegative RA.
Presenting New Data on Kidney Biomarkers
A key element of Exagen’s presentation will be the introduction of preliminary data regarding a groundbreaking kidney damage biomarker panel. This panel holds the potential to significantly alter the approach to early kidney disease management, particularly for patients suffering from lupus. This innovation aligns seamlessly with Exagen’s commitment to enhancing patient care through cutting-edge research.
A Robust Lineup of Abstracts
The accepted abstracts provide a comprehensive overview of the ongoing research initiatives at Exagen. Among the presentations, the plenary talk will specifically address how urinary Tenascin C functions as a predictor for kidney function loss in lupus nephritis, reinforcing the critical role biomarkers play in patient outcomes.
Other noteworthy presentations include:
- Title: A Machine Learning Classifier Enhances Diagnostic Performance for RA
- Title: A Novel Kidney-Specific Biomarker Panel Differentiates Lupus Nephritis from Diabetic Kidney Disease
- Title: Kidney-Specific Four-Protein Index for Early Kidney Damage Detection
- Title: Distinguishing SLE from ANA-Associated Disorders Using T Cell Biomarkers
- Title: Evaluating a Multianalyte Lupus Risk Score Incorporating Cell-bound Complement Activation Products
Each of these studies exemplifies Exagen’s dedication to research and development aimed at refining diagnostic tools for complex autoimmune conditions.
Advancing Autoimmune Diagnostics
Exagen Inc. remains committed to transforming the landscape of autoimmune disease diagnostics and management. Based in San Diego County, California, the company focuses on delivering clarity in decision-making for autoimmune conditions, significantly improving clinical outcomes through its innovative portfolio. The flagship product, AVISE® CTD, empowers clinicians to make earlier and more accurate diagnoses of complicated autoimmune diseases, including lupus and rheumatoid arthritis, aimed at enhancing the quality of patient care.
With a top-tier, CLIA-certified laboratory that's CAP-accredited, Exagen specializes in the testing of rheumatic diseases, providing timely and precise results through a suite of AVISE-branded tests. The emphasis on research and innovation underscores an unwavering commitment to patient-centered care and effective management of autoimmune diseases.
Connect with Exagen
To learn more about Exagen’s pioneering efforts in autoimmune diagnostics and to see the latest in their research findings, visit Exagen’s official website or follow them on LinkedIn for updates.
Frequently Asked Questions
What types of abstracts did Exagen present at ACR 2025?
Exagen presented six abstracts focusing on innovative diagnostics for lupus nephritis and rheumatoid arthritis, including novel biomarker panels and machine learning classifiers.
Who collaborated with Exagen on their plenary presentation?
The plenary presentation was developed in collaboration with Johns Hopkins University, highlighting advancements in lupus nephritis management.
What significant discovery will Exagen unveil regarding kidney damage?
Exagen will introduce a new kidney damage biomarker panel that has potential implications for the management of kidney diseases tied to lupus.
How does Exagen aim to improve patient care?
Exagen is focused on enhancing diagnostic accuracy and early intervention through innovative testing solutions for autoimmune diseases.
How can I stay updated on Exagen’s research and developments?
You can visit Exagen’s website or their LinkedIn page for the latest news and updates on their ongoing research initiatives and product offerings.
